January 27, 2022
Today’s announcement by Provention Bio regarding the resubmission of the Biologics License Application to the FDA represents significant progress in the prevention and treatment of type 1 diabetes (T1D).
Breakthrough T1D appreciates the Provention Bio team, clinical trial participants and all the researchers whose years of work have helped lead to this point. Alongside the Breakthrough T1D T1D Fund, we are proud to be early funders of teplizumab and will continue to support the research of disease-modifying therapies that put us on the critical pathway to preventing and ultimately curing T1D.
